This project investigates the regulation of metabolic flux in the hepatic tricarboxylic acid (TCA cycle) and its role in hepatic insulin resistance. The proposal follows up on key findings in the last funding cycle which indicate that anaplerotic/cataplerotic biosynthetic flux from the TCA cycle and oxidative flux of the TCA cycle are reciprocally regulated and that these pathways are elevated during hepatic insulin resistance. These findings challenge the role of impaired oxidative metabolism as an instigator of hepatic insulin resistance. Thus, we propose a novel hypothesis that elevated hepatic TCA cycle flux is a principal metabolic mediator of pathologies of hepatic insulin resistance by potentiating biosynthetic flux (e.g. gluconeogenesis) and oxidative stress. We test this hypothesis using conditional KO mice, state of the art 13C and 2H tracer based NMR and MS/MS isotopomer methods to evaluate hepatic metabolic fluxes of glucose, lipid and TCA cycle metabolism, and standard evaluation of signaling, gene expression and insulin sensitivity.
The first aim i s to test whether insulin action mediates dys/regulation of TCA cycle fluxes. We determine if acute genetic excision of insulin signaling recapitulates or exasperates elevated TCA cycle flux in HFD mice and whether acute deletion of FOXo1 ameliorates TCA cycle flux and oxidative stress during a HFD. Since these pathways are also subject indirect upregulation by substrate delivery during insulin resistance, the second aim is to determine the mechanism of co-regulation between cataplerotic biosynthesis and oxidative TCA cycle flux. While the acute regulation of these pathways by ATP, NADH and allosteric regulators are known, we will test whether AMPK and Sirt3 act as acute molecular regulators of flux through TCA cycle pathways. Finally, if elevated TCA cycle flux potentiates metabolic pathologies of hepatic insulin resistance, then suppressing TCA cycle pathways should prevent the onset of hepatic complications. Thus, the third aim is to determine if genetic suppression of the cataplerotic or the oxidative span of the TCA cycle results in improved metabolic, oxidative stress and inflammatory response to insulin resistance.

Public Health Relevance

Hepatic insulin resistance contributes to hyperglycemia, hyperlipidemia, fatty liver disease and related inflammatory processes which cause severe liver complications. This proposal addresses a metabolic mechanism that links nearly all complications of hepatic insulin resistance to the central metabolic pathway of the tricarboxylic acid cycle. Completion of this project will conceptually advance our knowledge of insulin resistance and provide a practical advance by identifying a novel therapeutic target against insulin resistance.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK078184-06
Application #
8440067
Study Section
Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
Program Officer
Laughlin, Maren R
Project Start
2007-04-01
Project End
2016-11-30
Budget Start
2012-12-17
Budget End
2013-11-30
Support Year
6
Fiscal Year
2013
Total Cost
$345,825
Indirect Cost
$128,325
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Kucejova, Blanka; Duarte, Joao; Satapati, Santhosh et al. (2016) Hepatic mTORC1 Opposes Impaired Insulin Action to Control Mitochondrial Metabolism in Obesity. Cell Rep 16:508-19
Burgess, Shawn C; Merritt, Mathew E; Jones, John G et al. (2015) Limitations of detection of anaplerosis and pyruvate cycling from metabolism of [1-(13)C] acetate. Nat Med 21:108-9
Gray, Lawrence R; Sultana, Mst Rasheda; Rauckhorst, Adam J et al. (2015) Hepatic Mitochondrial Pyruvate Carrier 1 Is Required for Efficient Regulation of Gluconeogenesis and Whole-Body Glucose Homeostasis. Cell Metab 22:669-81
Buescher, Joerg M; Antoniewicz, Maciek R; Boros, Laszlo G et al. (2015) A roadmap for interpreting (13)C metabolite labeling patterns from cells. Curr Opin Biotechnol 34:189-201
McCommis, Kyle S; Chen, Zhouji; Fu, Xiaorong et al. (2015) Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling. Cell Metab 22:682-94
Moreno, Karlos X; Moore, Christopher L; Burgess, Shawn C et al. (2015) Production of hyperpolarized (13)CO2 from [1-(13)C]pyruvate in perfused liver does reflect total anaplerosis but is not a reliable biomarker of glucose production. Metabolomics 11:1144-1156
Satapati, Santhosh; Kucejova, Blanka; Duarte, Joao A G et al. (2015) Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J Clin Invest 125:4447-62
Moreno, Karlos X; Satapati, Santhosh; DeBerardinis, Ralph J et al. (2014) Real-time detection of hepatic gluconeogenic and glycogenolytic states using hyperpolarized [2-13C]dihydroxyacetone. J Biol Chem 289:35859-67
Purmal, Colin; Kucejova, Blanka; Sherry, A Dean et al. (2014) Propionate stimulates pyruvate oxidation in the presence of acetate. Am J Physiol Heart Circ Physiol 307:H1134-41
Vigueira, Patrick A; McCommis, Kyle S; Schweitzer, George G et al. (2014) Mitochondrial pyruvate carrier 2 hypomorphism in mice leads to defects in glucose-stimulated insulin secretion. Cell Rep 7:2042-53

Showing the most recent 10 out of 32 publications